BCMA Targeted Therapies
6 drugsAbout BCMA
BCMA (B-Cell Maturation Antigen), encoded by TNFRSF17, is crucial for B cell survival and maturation. It regulates B cell development and homeostasis, making it a key target in oncology. BCMA is a receptor expressed on mature B cells.
BCMA is a significant oncology target, evidenced by 4 FDA-approved drugs. Genetic evidence offers moderate support, with associations to gastric carcinoma (score 0.52) and osteomyelitis (score 0.51). Strong eQTL/pQTL signals (max H4: 1.00) further support therapeutic targeting.
Four BCMA-targeting drugs are approved: BLENREP, ELREXFIO, LYNOZYFIC, and TECVAYLI. These include bispecific antibodies (2 drugs), an ADC, and another biologic. GSK, Pfizer, Regeneron, and Johnson & Johnson are key players in this space.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 84% attractiveness score.
- White space opportunity in Refractory Plasmablastic Lymphoma with only 2 trials.
- Emerging modalities (Antibody) signal innovation opportunity.
BCMA Genetic Evidence Moderate
Genetic evidence shows moderate support for BCMA, with a max score of 0.52.
Further research into the genetic links could strengthen the therapeutic rationale.
Evidence Across Diseases
4 totalGWAS and other genetic studies link TNFRSF17 to 4 diseases.
🔗 Colocalization Evidence 20 strong
max H4: 1.00eQTL/pQTL signals for TNFRSF17 colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top BCMA Drugs
Four companies have approved BCMA-targeting drugs, indicating a competitive landscape.
The presence of multiple players suggests moderate barriers to entry in this market.
| Drug | Company | Approved | Indications |
|---|---|---|---|
| BLENREP | GSK | 2025 | 1 |
| Abecma | Bristol-Myers Squibb | 2021 | - |
| Carvykti | Johnson & Johnson | 2022 | - |
BCMA Drug Modality Landscape
Modalities
Routes of Administration
BCMA requires biologic approaches (bispecific antibody), likely due to its structure or location.
Diversifying modalities beyond bispecific antibodies could provide a competitive advantage.
📈 Modality Evolution
Gene therapies pioneered BCMA targeting (2021), with adcs entering more recently (2025).
BCMA Clinical Trials 177 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 70 | 7 | 8 | 55 | 47% |
| Phase 2 | 73 | 5 | 4 | 64 | 56% |
| Phase 3 | 29 | 0 | 2 | 27 | 0% |
| Phase 4 | 5 | 0 | 0 | 5 | - |
Top Sponsors
By Modality
Top Conditions
Phase 3 Readout Calendar Pro
4 Phase 3 trials testing approved BCMA drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting BCMA. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
BCMA Drug Approval Timeline (2021 - 2025)
ABECMA is indicated for the treatment of adult patients w...
CARVYKTI is indicated for the treatment of adult patients...
The first BCMA-targeting drug was approved in 2022, with the most recent in 2025.
The recent approvals suggest continued innovation and potential for market growth.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 5 companies competing
- • Market share by company
Full Drug Portfolio
- • All 6 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 6-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 181 clinical trials targeting BCMA.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities